AbCellera Biologics Inc. (ABCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABCL Stock Price Chart Interactive Chart >
ABCL Price/Volume Stats
| Current price | $20.99 | 52-week high | $71.91 |
| Prev. close | $21.15 | 52-week low | $14.51 |
| Day low | $20.47 | Volume | 2,619,100 |
| Day high | $21.46 | Avg. volume | 1,665,613 |
| 50-day MA | $17.36 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 5.85B |
AbCellera Biologics Inc. (ABCL) Company Bio
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.
Latest ABCL News From Around the Web
Below are the latest news stories about AbCellera Biologics Inc that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
Berkeley Lights: Short Seller Report Raises A Few Legitimate QuestionsOn September 15th, Berkeley Lights (BLI) was the subject of an extremely long and messy report by short seller Scorpion Capital, outlining its bearish thesis on the company. As a result of this thesis and of the press given by major financial networks, shares of Berkeley have tanked roughly 30%... |
AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic AntibodiesAbCellera Biologics Inc (NASDAQ: ABCL ) and Everest Medicines Limited have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help expand Everest''s portfolio of novel medicines Full story available on Benzinga.com |
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies10-target partnership leverages AbCellera''s technology to accelerate Everest''s pipeline of novel, innovative medicines to patients VANCOUVER, British Columbia and SHANGHAI , Sept. 23, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest''s portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology. "We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond," said Carl Hansen , Ph.D., CEO and President of ... |
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19VANCOUVER, British Columbia, September 21, 2021--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 |
FDA Extends EUA for AbCellera’s Bamlanivimab; Shares Rally 19.8%The U.S. Food and Drug Administration has expanded the emergency use authorization for AbCellera Biologics’ (ABCL) bamlanivimab, which is administered with etesevimab to prevent SARS-CoV-2 infection or symptomatic COVID-19. Following the news, shares of the biotechnology firm rallied 19.8% in Thursday’s extended trade. The stock further gained 16.7% in pre-market trading session on Friday. The expanded authorization is based on the Phase 3 BLAZE-2 trial that showed bamlanivimab helped in preventing COVID-19 and reducing the risk of contracting the disease by up to 80% in nursing home residents and up to 57% among residents and staff of long-term care facilities. |
ABCL Price Returns
| 1-mo | 19.40% |
| 3-mo | -1.36% |
| 6-mo | -38.19% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.84% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...